The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
Open accessAbstract
BACKGROUND: We examined the potential of metformin (MET) to enhance non-small cell lung cancer (NSCLC) responses to ionising radiation (IR). METHODS: Human NSCLC cells, mouse embryonic fibroblasts from wild-type and AMP-activated kinase (AMPK) α1/2-subunit(-/-) embryos (AMPKα1/2(-/-)-MEFs) and NSCLC tumours grafted into Balb/c-nude mice were treated with IR and MET and subjected to proliferation, clonogenic, immunoblotting, cell cycle and apoptosis assays and immunohistochemistry (IHC). RESULTS: Metformin (2.5 μM-5 mM) inhibited proliferation and radio-sensitised NSCLC cells. Metformin (i) activated the ataxia telengiectasia-mutated (ATM)-AMPK-p53/p21(cip1) and inhibited the Akt-mammalian target of rapamycin (mTOR)-eIF4E-binding protein 1 (4EBP1) pathways, (ii) induced G1 cycle arrest and (iii) enhanced apoptosis. ATM inhibition blocked MET and IR activation of AMPK. Non-small cell lung cancer cells with inhibited AMPK and AMPKα1/2(-/-)-MEFs were resistant to the antiproliferative effects of MET and IR. Metformin or IR inhibited xenograft growth and combined treatment enhanced it further than each treatment alone. Ionising radiation and MET induced (i) sustained activation of ATM-AMPK-p53/p21(cip1) and inhibition of Akt-mTOR-4EBP1 pathways in tumours, (ii) reduced expression of angiogenesis and (iii) enhanced expression of apoptosis markers. CONCLUSION: Clinically achievable MET doses inhibit NSCLC cell and tumour growth and sensitise them to IR. Metformin and IR mediate their action through an ATM-AMPK-dependent pathway. Our results suggest that MET can be a clinically useful adjunct to radiotherapy in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Steinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“Retrospective analysis suggested that MET may enhance chemotherapy responses in women with breast cancer (Jiralerspong et al, 2009).”
BackgroundSahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 2×
“More effective modulation of p53/ p21cip1 and mTOR by MET in irradiated cells is expected to inhibit cycling further and promote G1 arrest, which we did observe (Figure 3) and has been described by others (Ben Sahra et al, 2008; Rattan et al, 2011).”
BackgroundResultCell death modalities: classification and pathophysiological implications
Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402148 · Cited by 832 · cited 1×
“However, it remains highly controversial whether autophagy is a reliable marker of cell survival or cell death in cells subjected to cytotoxic therapy (Galluzzi et al, 2007).”
BackgroundMetformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3471 · Cited by 450
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F., Chong, W. Y., Hummersone, M., Rigoreau, L., Menear, K. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0519 · Cited by 385
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 355
Nagata, D., Mogi, M., & Walsh, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300643200 · Cited by 331 · cited 1×
“AMP-activated kinase is suggested to participate in angiogenesis (Nagata et al, 2003) and MET was suggested to normalise tumour vasculature in breast cancer and inhibit angiogenesis in ovarian cancer xenografts (Rattan et al, 2011).”
BackgroundBussink, J., van der Kogel, A. J., & Kaanders, J. H. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70073-1 · Cited by 326
Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011) · Neoplasia · doi:10.1593/neo.11148 · Cited by 316
Shi, W.-Y., Xiao, D., Wang, L., Dong, L.-H., Yan, Z.-X., Shen, Z.-X., Chen, S.-J., Chen, Y., & Zhao, W.-L. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.13 · Cited by 308
Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Rocha, G. Z., Dias, M. M., Ropelle, E. R., Osório-Costa, F., Rossato, F. A., Vercesi, A. E., Saad, M. J. A., & Carvalheira, J. B. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2243 · Cited by 305
Skinner, H. D., Sandulache, V. C., Ow, T. J., Meyn, R. E., Yordy, J. S., Beadle, B. M., Fitzgerald, A. L., Giri, U., Ang, K. K., & Myers, J. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2260 · Cited by 293
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
Song, C. W., Lee, H., Dings, R. P. M., Williams, B., Powers, J., Santos, T. D., Choi, B.-H., & Park, H. J. (2012) · Scientific Reports · doi:10.1038/srep00362 · Cited by 280
Autophagy contributes to resistance of tumor cells to ionizing radiation
Chaachouay, H., Ohneseit, P., Toulany, M., Kehlbach, R., Multhoff, G., & Rodemann, H. P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.002 · Cited by 264
Sanli, T., Rashid, A., Liu, C., Harding, S., Bristow, R. G., Cutz, J.-C., Singh, G., Wright, J., & Tsakiridis, T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.005 · Cited by 216
Self-citationZakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213
Metformin in Breast Cancer: Time for Action
Goodwin, P. J., Ligibel, J. A., & Stambolic, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1630 · Cited by 200
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 177
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/dc06-0997 · Cited by 175
mTOR signaling: implications for cancer and anticancer therapy
Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D., & Sonenberg, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602902 · Cited by 170
mTOR phosphorylated at S2448 binds to raptor and rictor
Rosner, M., Siegel, N., Valli, A., Fuchs, C., & Hengstschläger, M. (2010) · Amino Acids · doi:10.1007/s00726-008-0230-7 · Cited by 162
Sanli, T., Linher‐Melville, K., Tsakiridis, T. K., & Singh, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032035 · Cited by 139
Self-citationTanaka, T., Munshi, A., Brooks, C., Liu, J. X., Hobbs, M. L., & Meyn, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1606 · Cited by 138
PI3K and mTOR inhibitors — a new generation of targeted anticancer agents
Brachmann, S. M., Fritsch, C. M., Maira, S.-M., & García-Echeverría, C. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.011 · Cited by 114
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene
Carretero, J., Medina, P. P., Pı́o, R., Montuenga, L. M., & Sánchez‐Céspedes, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207502 · Cited by 114
Menéndez, J. A., Cufí, S., Oliveras‐Ferraros, C., Martín-Castillo, B., Joven, J., Vellón, L., & Vázquez‐Martín, A. (2011) · Aging · doi:10.18632/aging.100407 · Cited by 91
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response
Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Martin-Castillo, B., & Menendez, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15423 · Cited by 81
Jimeno, A., Rudek, M. A., Kulesza, P., Ma, W. W., Wheelhouse, J., Howard, A., Khan, Y. W., Zhao, M., Jacene, H. A., Messersmith, W. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2347 · Cited by 77
Sanli, T., Liu, C., Rashid, A., Hopmans, S., Tsiani, E., Schultz, C., Farrell, T. J., Singh, G., Wright, J. R., & Tsakiridis, T. K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182049d8b · Cited by 76
Self-citationSanli, T., Storozhuk, Y., Linher‐Melville, K., Bristow, R. G., Laderoute, K. R., Viollet, B., Wright, J. R., Singh, G., & Tsakiridis, T. K. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.11.014 · Cited by 50
Self-citationCancer Prevention With a Diabetes Pill?
Taubes, G. (2012) · Science · doi:10.1126/science.335.6064.29 · Cited by 50
Vázquez‐Martín, A., Oliveras‐Ferraros, C., Barco, S. D., Martı́n-Castillo, B., & Menéndez, J. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5456 · Cited by 35
Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer.
Curran, W. J. (2003) · PubMed · Cited by 29
AP-1 as a Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone
Mak, I. W. Y., TURCOTTE, R. E., Popović, S., Singh, G., & Ghert, M. A. (2011) · Biochemistry Research International · doi:10.1155/2011/164197 · Cited by 21
Self-citationTsakiridis, T. K., Cutz, J., Singh, G., Hirte, H. W., Okawara, G. S., Corbett, T., Sur, R. K., Cai, W., Whelan, T. J., & Wright, J. R. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6094 · Cited by 18
Self-citation
Cited by
Targeting mitochondria metabolism for cancer therapy
Weinberg, S. E., & Chandel, N. S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1712 · Cited by 1,381
ROS homeostasis and metabolism: a dangerous liason in cancer cells
Panieri, E., & Santoro, M. M. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.105 · Cited by 1,151
Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
Barron, C. C., Bilan, P. J., Tsakiridis, T., & Tsiani, E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.007 · Cited by 435
Self-citationTargeting AMPK for cancer prevention and treatment
Li, W., Saud, S. M., Young, M. R., Chen, G., & Hua, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3629 · Cited by 355
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
Metadata
- Authors
- Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T.
- Venue
- British Journal of Cancer
- Published
- 2013-04-30
- Volume
- 108
- Issue
- 10
- Pages
- 2021-2032
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2076908467
- Cited by
- 273
- References
- 48
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.